OTC Markets OTCPK - Delayed Quote USD

Coloplast A/S (CLPBF)

97.22

+0.71

+(0.74%)

At close: June 5 at 8:00:00 PM EDT

Coloplast A/S - Invitation to Coloplast's Capital Markets Day on 2 September 2025

The event will take place on Tuesday, 2 September 2025 at Clarion Hotel (Copenhagen airport)Ellehammersvej 20, 2770 Kastrupfrom 10.30 - 17.00 CEST(Central European Summer Time) Coloplast invites institutional investors, equity analysts and media to attend our 2025 Capital Markets Day.The event will be held in person at Clarion Hotel in Copenhagen, Denmark, with the option to join virtually for the plenary session.The purpose of the event is to give institutional investors and financial analysts

GlobeNewswire 6 days ago

CLPBF
+0.74%

CLPBY
Coloplast AS (CLPBF) Q2 2025 Earnings Call Highlights: Navigating Growth Challenges and ...

Coloplast AS (CLPBF) reports a 6% organic growth and revises annual expectations amidst product recalls and market slowdowns.

GuruFocus.com last month

COLO-B.CO
Coloplast A/S - Announcement no. 04/2025 - Interim Financial Report, H1 2024/25

Interim financial results, H1 2024/25 1 October 2024 - 31 March 2025 Coloplast delivered 6% organic growth in Q2, impacted by the product recall in Interventional Urology and a softer quarter in Ostomy Care. Q2 EBIT margin1 held steady at 27%. Reported revenue in DKK grew 5%, impacted by the Skin Care divestment. Organic growth rates by business area: Ostomy Care 4%, Continence Care 8%, Voice and Respiratory Care 7%, Advanced Wound Care 10% and Interventional Urology -1%.Growth in Chronic Care w

GlobeNewswire last month

CLPBF
+0.74%

CLPBY
Coloplast A/S CEO Kristian Villumsen steps down as of today

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy period, the Board of Directors has decided to initiate the search for a new CEO to lead Coloplast into its next phase of long-term, sustainable growth and value creation. As a result, President and CEO, Kristian Villumsen, steps down as of today. To ensure continuity, the Chair of the Board Lars Ra

GlobeNewswire last month

CLPBF
+0.74%

CLPBY
Stocks to watch this week: Palantir, TSMC, Novo Nordisk and JD Wetherspoon

Earnings preview of key companies reporting this week and what to look out for.

Yahoo Finance UK last month

ARM

NXGPF

NXGPY
Coloplast A/S Revised guidance for FY 2024/25

Coloplast revises financial guidance for FY 2024/25 and pre-announces H1 2024/25 key financial figures Coloplast revises the guidance on organic growth and EBIT margin before special items for FY 2024/25. The organic growth is now expected to be around 7%, from previously 8-9%. The EBIT margin before special items is now expected to be 27-28%, from previously around 28%. Key financial figures and developments in Q2: Group organic growth was 6% in Q2. The EBIT margin before special items was 27%.

GlobeNewswire last month

CLPBF
+0.74%

CLPBY
Coloplast A/S - H1 2024/25 Earnings Release - Invitation to conference call on 6 May 2025 at 11.00am CEST

Tuesday, 6 May 2025 at 11.00 - 12.00am CESTIn connection with the publication of Coloplast’s interim financial results for H1 2024/25, to be released same day around 07.30am CEST, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the event. Colo

GlobeNewswire last month

CLPBF
+0.74%

CLPBY
Coloplast AS (CLPBF) Q1 2025 Earnings Call Highlights: Strong Organic Growth and Strategic ...

Coloplast AS (CLPBF) reports robust 8% organic growth and a 27% EBIT margin, while addressing challenges in Interventional Urology and tax impacts.

GuruFocus.com 4 months ago

COLO-B.CO
Coloplast A/S - Allocation of Share Options

Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below transactions concern allocation of share options. For further details, reference is made to Coloplast’s Remuneration Policy. The policy is available on the group website at this address: https://investor

GlobeNewswire 4 months ago

CLPBF
+0.74%

CLPBY
Coloplast A/S - Interim Financial Report, Q1 2024/25

2024/25 Interim financial results, Q1 2024/25 1 October 2024 - 31 December 2024 Coloplast delivered 8% organic growth and an EBIT margin1 of 27% in Q1, in line with expectations. Reported revenue in DKK grew 6% and included negative impact from the divestment of Skin Care and currencies. Organic growth rates by business area: Ostomy Care 7%, Continence Care 7%, Voice and Respiratory Care 11%, Advanced Wound Care 12% and Interventional Urology 1%.Growth in Chronic Care was driven by solid contrib

GlobeNewswire 4 months ago

CLPBF
+0.74%

CLPBY
Stocks to watch this week: Amazon, Palantir, Disney, Novo Nordisk and AstraZeneca

Earnings preview of key companies reporting this week and what to look out for.

Yahoo Finance UK 4 months ago

^FTSE

DIS

HMC
Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET (correction)

Tuesday, 4 February 2025 at 11.00 - 12.00am CET (corrected from 10.00 - 11.00am CET in an earlier version of this invitation)In connection with the publication of Coloplast’s interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The

GlobeNewswire 4 months ago

CLPBF
+0.74%

CLPBY
Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET

Tuesday, 4 February 2025 at 10.00 - 11.00am CETIn connection with the publication of Coloplast’s interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the event. C

GlobeNewswire 4 months ago

CLPBF
+0.74%

CLPBY
Coloplast A/S - Decisions at the Annual General Meeting 2024

Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2023/24 was approved.Distribution of year-end dividend of DKK 17.00 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half- year result, this brings the total dividend paid for the financial year 2023/24 to DKK 22.00 per share

GlobeNewswire 6 months ago

CLPBF
+0.74%

CLPBY
Coloplast divests core Skin Care product portfolio

The divestment is part of a strategic initiative to simplify business operations and improve profitability in the Advanced Wound Care business area. Revenue from the core Skin Care business amounted to around DKK 400 million in FY 2023/24, with an operating profitability level significantly below the group EBIT margin. Coloplast’s FY 2024/25 financial guidance1 of organic revenue growth at 8-9% and an EBIT margin before special items of around 28% is unchanged and already includes the divestment

GlobeNewswire 6 months ago

CLPBF
+0.74%

CLPBY
Kerecis included on the list of covered products for Diabetic Foot Ulcers in the final LCD policy

On 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD)1 policy regarding skin substitute grafts/cellular and tissue-based products for the treatment of Diabetic Foot Ulcers (DFUs) and venous leg ulcers (VLUs) in the Medicare population. The final LCD policy confirms the introduction of a technical qualification and a clinical efficacy qualification, proposed in a draft LCD policy2 earlier this year. The final decision also i

GlobeNewswire 6 months ago

CLPBF
+0.74%

CLPBY
Coloplast A/S - Notice of Annual General Meeting 2024

The Annual General Meeting of Coloplast A/S will be held onThursday, 5 December 2024 at 3:30 pm CETat the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark.The notice of the Annual General Meeting is enclosed. For further information, please contact Investors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111 Aleksandra Dimovska Vice President, Investor Relations Tel. +45 4911 1800 / +45 4911 2458 Email: dk

GlobeNewswire 6 months ago

CLPBF
+0.74%

CLPBY
Coloplast AS (CLPBF) Q4 2024 Earnings Call Highlights: Strong Organic Growth and Strategic ...

Coloplast AS (CLPBF) reports robust financial performance with 8% organic growth and strategic product launches, despite facing supply disruptions and competitive pressures.

GuruFocus.com 6 months ago

COLO-B.CO
Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24

Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24 FY 2023/24 organic growth of 8% and 27% EBIT margin1. Reported revenue in DKK grew 10% to DKK 27,030 million. Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 11%, Advanced Wound Care 10% (Advanced Wound Dressings 8%) and Interventional Urology 5%. Kerecis contributed 4%-points to reported growth, with an underlying growth of around 35%, in line with expectations. EBIT1 was DK

GlobeNewswire 6 months ago

CLPBF
+0.74%

CLPBY
Coloplast A/S - Full-Year Financial Results 2023/24

2023/24 Announcement of full-year financial results 1 October 2023 - 30 September 2024 Coloplast delivered Q4 organic growth of 8% and an EBIT margin1 of 26%, which was negatively impacted by extraordinary costs and currencies. Reported revenue in DKK grew 12% with 3%-pts contribution from the Kerecis acquisition (two months). Organic growth rates by business area: Ostomy Care 6%, Continence Care 10%, Voice and Respiratory Care 12%, Advanced Wound Care 10% (Advanced Wound Dressings 4%) and Inter

GlobeNewswire 6 months ago

CLPBF
+0.74%

CLPBY

Performance Overview

Return	CLPBF	OMX Copenhagen 25 Index (^OMXC25)
YTD	-10.90%	+1.93%
1-Year	-18.66%	-9.87%
3-Year	-14.51%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Coloplast A/S (CLPBF)

Coloplast A/S - Invitation to Coloplast's Capital Markets Day on 2 September 2025

Coloplast AS (CLPBF) Q2 2025 Earnings Call Highlights: Navigating Growth Challenges and ...

Coloplast A/S - Announcement no. 04/2025 - Interim Financial Report, H1 2024/25

Coloplast A/S CEO Kristian Villumsen steps down as of today

Stocks to watch this week: Palantir, TSMC, Novo Nordisk and JD Wetherspoon

Coloplast A/S Revised guidance for FY 2024/25

Coloplast A/S - H1 2024/25 Earnings Release - Invitation to conference call on 6 May 2025 at 11.00am CEST

Coloplast AS (CLPBF) Q1 2025 Earnings Call Highlights: Strong Organic Growth and Strategic ...

Coloplast A/S - Allocation of Share Options

Coloplast A/S - Interim Financial Report, Q1 2024/25

Stocks to watch this week: Amazon, Palantir, Disney, Novo Nordisk and AstraZeneca

Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET (correction)

Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET

Coloplast A/S - Decisions at the Annual General Meeting 2024

Coloplast divests core Skin Care product portfolio

Kerecis included on the list of covered products for Diabetic Foot Ulcers in the final LCD policy

Coloplast A/S - Notice of Annual General Meeting 2024

Coloplast AS (CLPBF) Q4 2024 Earnings Call Highlights: Strong Organic Growth and Strategic ...

Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24

Coloplast A/S - Full-Year Financial Results 2023/24

Performance Overview